For decades, men diagnosed with prostate cancer have faced a dilemma: live with the disease under active surveillance, watchful waiting that comes with anxiety, or undergo radical treatment through surgery or radiation, which can bring significant side effects such as incontinence and erectile dysfunction.
Now, a new frontier is emerging in urology and oncology: focal therapy. Instead of removing or irradiating the entire prostate gland, focal therapy targets only the cancerous regions, preserving healthy tissue and, with it, much of a patient’s quality of life. Though still in its early stages, focal therapy has begun reshaping the conversation around prostate cancer care in Europe, the UK, and Asia—and may soon redefine what it means to treat one of the world’s most common cancers.
1. Understanding Prostate Cancer: Scope of the Challenge
Prostate cancer is the second most common cancer in men worldwide. In countries with aging populations, including Malaysia, Singapore, Japan, and much of Europe, incidence rates are climbing as life expectancy increases and screening becomes more widespread.
Traditional treatment options fall into two main categories:
- Active surveillance: Doctors monitor the cancer with regular PSA (prostate-specific antigen) tests, MRIs, and biopsies. Intervention only occurs if the cancer grows or spreads. This approach avoids unnecessary side effects but can cause anxiety and uncertainty.
- Radical therapies: Prostatectomy (surgical removal of the gland) or full-gland radiation therapy aim to eliminate cancer entirely. While effective, they often bring serious, long-lasting side effects: urinary leakage, bowel dysfunction, and impotence.
This binary choice has left a significant gap: patients with localized, low- to intermediate-risk cancer often feel overtreated by radical therapy but underprotected by surveillance.
Focal therapy seeks to fill that gap.
2. What Is Focal Therapy?
Focal therapy is sometimes described as “lumpectomy for the prostate”, a targeted intervention that treats only diseased portions of the gland while preserving normal tissue. The approach draws on advances in imaging and ablation technology, allowing doctors to pinpoint cancerous zones and destroy them precisely.
Key Modalities of Focal Therapy
- High-Intensity Focused Ultrasound (HIFU):
Uses sound waves to generate heat at specific points within the prostate, “cooking” tumor cells while sparing surrounding tissue. - Cryotherapy:
Involves inserting thin probes that freeze cancer cells to death with liquid nitrogen or argon gas, followed by thaw cycles. - Laser Ablation:
Applies laser fibers directly into the prostate to burn targeted regions, guided by MRI or ultrasound. - Photodynamic Therapy (PDT):
Uses light-sensitive drugs activated by lasers to kill cancer cells while minimizing impact on healthy cells. - Irreversible Electroporation (NanoKnife):
A newer modality that uses electrical pulses to puncture cancer cell membranes, leading to cell death without heat or freezing.
Each technique shares the same philosophy: precision over radicality.
3. How Focal Therapy Works in Practice
Imagine a patient in his 60s diagnosed with a small, localized prostate tumor. Traditionally, doctors would recommend removing the entire gland or irradiating it, regardless of the tumor’s size. With focal therapy, however, an MRI pinpoints the exact dimensions and location of the tumor.
Under general anesthesia, a surgeon inserts a probe via the rectum or perineum into the prostate. Guided by imaging, the device delivers energy, whether heat, cold, or light, directly to the tumor. The procedure typically lasts 1–2 hours. Patients often return home the same day, with minimal blood loss and faster recovery compared to surgery.
Bloomberg’s reporting highlighted a case in Wimbledon, where a 10 mm tumor was ablated using ultrasound waves. Unlike full prostatectomy, which can require weeks of recovery and carries high risk of side effects, the patient was expected to leave hospital within hours, resuming near-normal life within days.
4. Benefits of Focal Therapy
a) Quality of Life Preservation
Perhaps the most compelling argument for focal therapy is its potential to spare urinary and sexual function. Since surrounding healthy tissue remains intact, rates of incontinence and erectile dysfunction are significantly lower compared to surgery or radiation.
b) Reduced Morbidity
Hospital stays are shorter, recovery times are faster, and complication risks are lower. This makes focal therapy attractive for patients with co-morbidities who may not tolerate radical surgery.
c) Repeatability
If cancer recurs, focal therapy can often be repeated. It doesn’t preclude future radical treatment, making it a flexible option within a lifelong cancer management strategy.
d) Cost and Resource Efficiency
Shorter hospital stays and fewer complications could reduce healthcare costs. While advanced imaging is expensive, the long-term economics may prove favorable if side-effect management is minimized.
5. Limitations and Risks
a) Patient Selection
Focal therapy is not for everyone. Patients with aggressive, multifocal, or advanced-stage cancer may require whole-gland treatment. Selection requires meticulous imaging and biopsy analysis.
b) Imaging Gaps
Even with MRI, small tumors may go undetected. If untreated cancerous regions exist, recurrence risk rises. This makes follow-up crucial.
c) Lack of Long-Term Data
Most focal therapy studies offer 5–10 years of outcomes. While results are promising, critics argue that radical therapy still has the strongest long-term evidence base.
d) Psychological Factors
Some patients feel anxious knowing part of the prostate remains untreated. Trust in monitoring systems is essential.
6. The Global Research Landscape
Focal therapy is still considered “emerging” in many regions, but global momentum is growing:
- UK: Pioneering centers in London and Oxford are running long-term studies comparing HIFU and cryotherapy outcomes with radical surgery.
- Europe: Germany, France, and the Netherlands are integrating focal therapy into national guidelines for selected patients.
- US: Adoption is slower due to FDA hurdles, though clinical trials are ongoing.
- Asia: Japan and South Korea are investing in research, while Malaysia and Singapore watch developments closely.
A recent study from University College London showed 90% of men remained cancer-free five years after HIFU focal therapy, with lower rates of erectile dysfunction and incontinence compared to radical treatments.
7. Patient Perspectives: Stories of Hope and Caution
Patients who undergo focal therapy often describe it as “life-changing”, not because it eradicates all fear, but because it allows them to live more normally.
- John, 62 (UK): “I was terrified of surgery because of the side effects. After HIFU, I was back home in a day. I still need check-ups, but I can live without a catheter and without losing intimacy with my wife.”
- Ahmad, 59 (Malaysia): “I wanted focal therapy but couldn’t find a local center offering it. I had to travel to Singapore. The procedure went well, but follow-up here is difficult.”
- Peter, 67 (US): “My insurance wouldn’t cover focal therapy, so I chose surgery. It feels unfair, patients should have all options available.”
These testimonies underline the promise and accessibility challenges.
8. Implications for Asia and Malaysia
For Asia, where prostate cancer incidence is climbing with aging demographics, focal therapy could fill a critical need. But implementation depends on several factors:
- Infrastructure: High-quality MRI and interventional radiology facilities are essential.
- Training: Urologists need specialized training in focal techniques.
- Policy: Governments must consider coverage under national health insurance schemes.
- Public Awareness: Patients need education on alternatives beyond “surveillance or surgery.”
Malaysia, for example, has steadily rising prostate cancer cases but limited adoption of advanced modalities. Collaboration with Singaporean centers could accelerate regional expertise.
9. Future Directions in Focal Therapy
The future may see focal therapy paired with AI-driven diagnostics and genomic profiling:
- AI in Imaging: Algorithms can help detect hidden lesions on MRI, improving targeting accuracy.
- Biomarkers: Blood and urine tests may predict which cancers respond best to focal treatment.
- Combination Therapy: Some trials explore focal ablation followed by low-dose systemic treatment to ensure microscopic disease control.
- Robotics: Robotic probes could further refine precision and consistency.
As technology improves, focal therapy may move from “niche option” to mainstream first-line treatment for select patients.
Focal therapy represents more than a medical technique, it symbolizes a philosophical shift in oncology. It challenges the idea that more radical is always better, instead asking: Can we treat cancer while preserving life’s quality?
For now, it is not a universal solution. But for men caught between the extremes of inaction and invasive surgery, focal therapy offers something profound: a middle path.
If adopted carefully, with robust trials and equitable access, it may become one of the defining advances in cancer care of the 21st century.
